Dr. Giedlin iscurrently the VP, Head of Tech Ops at Senti BioSciences supporting theallogeneic NK-CAR programs. Before his joining Senti, he led the PD groups atPACT Pharma (non-viral process for generating autologous neoTcR+ T cells),Poseida (non-viral process for generating autologous CAR-T’s), and Novartis(clinical and commercial manufacturing process for Kymriahâ). His experience covers over 25 years of variousapproaches to harness the immune response to treat cancer and infectiousdisease, starting with Proleukinâ rIL-2 (aldesleukin; Chiron), Oncolytic adenovirus(Onyx), Listeria-based cancer vaccines (Cerus), and CCR5 knockout CD4+ T cellsfor HIV+ patients (Sangamo). Inaddition, he led the implementation of AAV clinical manufacturing to supportthe Hemophilia, LSD, and neurodegenerative disease programs.